

COMPANY PROFILE



Dr. Achim Freisleben
Managing Director
achim.freisleben@nuvisan.com



Daniel Szerman
Managing Director
daniel.szerman@nuvisan.com

History and Mission

NUVISAN is the only fully integrated European CRO/CDMO providing all relevant GxP services from one single source. With a track record of over 40 years, we are connecting all services and support along the value chain from early drug discovery up to completions of early phase - from the molecule discovery to the patient. Our capabilities are distributed over six locations in Germany and France with a total space of over 55.000 m² and over 1.000 highly educated employees. **Your Value is Our Business.**

Highlights

The **NUVISAN** group is a CRO and CDMO with its headquarters in Neu-Ulm and six sites in Germany and France.

NUVISAN offers integrated solutions along the drug development value chain from early discovery to the patient with all supporting services.

In 2020 NUVISAN acquired a research unit from Bayer, which completes the development services in the very early beginning of the value chain.

Having a proven track record to include over 40 years of continuous service is a testimony to the operational excellence and the experience of NUVISAN's 1.000 highly qualified employees.



Neu-Ulm



Berlin



Sophia-Antipolis

NUVISAN GmbH
Wegenerstrasse 13
89231 Neu-Ulm, Germany

Tel. +49 731 9840-0
Fax +49 731 9840-280

E-Mail: hello@nuvisan.com

BVMA member since 1995
Audits passed in 2000, 2003, 2006,
2009, 2012, 2015 and 2018

NUVISAN



www.nuvisan.com

Services

ALL SERVICES BY DIVISION

EARLY DRUG DISCOVERY

- Lead Discovery
- Life Science Chemistry
- Therapeutic Research
- Preclinical Compound Profiling
- Library & Digital Life Sciences

NON-CLINICAL SERVICES

- In vitro DMPK packages for discovery and development; regulatory DDI
- In vivo DMPK in rodents, dogs or non human primates
- Analytical chemistry, discovery and toxicokinetic
- Isotope labeling, radiosynthesis (¹⁴C, ³H), stable isotopes, reference standards

CLINICAL SERVICES

- Phase 1 Unit at two sites**
- Clinical Conduct in Nuvisan's 140 bed unit
- Data Science Services (Data Management and Bio-Statistics)
- Clinical Project Management
- Regulatory Affairs
- Medical Writing

Clinical Safety Laboratory & Central Lab Services

- Central Laboratory & Biomarker Projects
- In-house Support of Phase-1
- Latin America Phase 1 – 4**
- Monitoring Services

LABORATORY SERVICES

- Bioanalytics
- Small Molecules (LC/MS)
- Large Molecules (ELISA, Ligand Binding Assays)
- Cell Culture (Soluble Marker & Cell Surface Marker, Cell Activity)
- Pharmaceutical Analytics (Small & Large Molecules / ELISA, CE, LC/MS, CESI-MS)
- Clinical Trial Supplies (Packaging, Distribution & Manufacturing)